Andorra vs Europe (WHO region): Previously treated cases tested for RR-/MDR-TB
Andorra
100.0%
in 2014
Europe (WHO region)
90.0%
in 2024
Andorra rank
1st
Europe (WHO region) rank
2nd
Previously treated cases tested for RR-/MDR-TB over time
- Andorra
- Europe (WHO region)
How they compare
Andorra currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Andorra's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 1 time across 5 shared years of data; in 2006 it was Europe (WHO region) ahead.
Andorra ranks 1st and Europe (WHO region) ranks 2nd of 180 countries.
Across the 2 decades both report, Andorra averaged higher in 1 and Europe (WHO region) in 1.
Head to head by decade
| Decade | Andorra | Europe (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 16.7% | 25.7% | 9.0% | Europe (WHO region) |
| 2010s | 100.0% | 43.5% | 56.5% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Andorra or Europe (WHO region)?
- Andorra, at 100.0% against 90.0% in Europe (WHO region) as of 2014.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Andorra and Europe (WHO region)?
- 10.0%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Europe (WHO region)?
- 5 years are reported by both, from 2006 to 2014.
- How do Andorra and Europe (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Andorra ranks 1st and Europe (WHO region) ranks 2nd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.